AR and breast cancer: It is plausible that HER2‐low BC is linked to the LAR subtype of TNBC, as evidenced by the higher prevalence of AR positivity in HER2‐low BC and the elevated occurrence of the HER2‐enriched subtype according to the PAM50 classification system in patients with LAR TNBC.37